Public Relations


"Starting with our proprietary positioning and messaging methodology – LHS Immersion® – we partner with clients to develop integrated communications’ programs that build influence and awareness and reach the right stakeholders, with the right messages at the right time."

--Sharon Correia

Our Public Relations services help our clients educate target audiences about their unique value proposition through corporate and product story development. We build influence and awareness to position our clients and/or their products as the right choice for critical stakeholders.
We provide:

Douglas Russell

Senior Vice President & General Manager

Phone: 617-374-8800 x108
Email: drussell@lavoiehealthscience.com

Sharon Correia

Vice President, Integrated Communications

Phone: 617-374-8800 x105
Email: scorreia@lavoiehealthscience.com

Bell Ringer Merit Award 2016

PAIN: a conversation with highly-regarded speakers, digital content, advocacy group outreach, and media relations. The event drew a standing-room crowd, including several leaders and advocacy groups, to a premier Boston hotel for a networking reception and panel.

@LaVoieGroup

- 17 hours ago

RT @RaganComms: Quality writing and storytelling matter more than ever. Join us in Boston for the Writing for PR and Corporate Comms Confe…
@LaVoieGroup

- 21 hours ago

We are happy to announce the addition of XenoTherapeutics to our client roster! LHS will help them build out their… https://t.co/kPomJDpUpQ
@LaVoieGroup

- 21 hours ago

From @Redbones BBQ to lemon cupcakes, LHS sure knows how to throw a bridal shower! Surprise Ella! We're wishing you… https://t.co/kDMmGWBRKR
@LaVoieGroup

- 23 hours ago

RT @DDNewsOnline: Emmaus announces +ve results in Ph3 #clinicaltrial of L-glutamine vs #SickleCell in subjects 5+ yrs 25% fewer sickle cel…

Example of Public Relations: Panel Development

PAIN: a Conversation brought together industry leaders to participate in a discussion about opioid addition and the need for alternatives. This panel discussion drew nearly 100 clinicians, scientists, patient advocates, patients, investors and biotech/pharma industry professionals.